Expert Panel Review Further Validates Use of ZORYVE (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

• Eight of nine experts expressed feeling “extremely confident” about prescribing ZORYVE foam to patients of diverse skin and hair types, including individuals with previous hair treatments, based on review of formulation data
  
• Crodafos CES, used in ZORYVE foam, is suitable for a wide variety of skin and hair types
• Findings from this formulation review underscore the suitability of ZORYVE foam for use on all affected areas of the body, and all hair types, in the management of seborrheic dermatitis
  

WESTLAKE VILLAGE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the Journal of Clinical and Aesthetic Dermatology (JCAD) published the outcomes of a comprehensive evaluation by an expert dermatologist panel assessing the formulation ingredients of ZORYVE (roflumilast) topical foam, 0.3%. ZORYVE foam is a once-daily steroid-free treatment for seborrheic dermatitis. The published article supports the use of ZORYVE foam in all hair and skin types.

“Seborrheic dermatitis is a common inflammatory skin condition that can affect individuals across all ages and demographics, and a spectrum of hair types. In addition, certain hair care practices can exacerbate the severity of the symptoms or complicate treatment options. As such, there is a significant need for versatile and well tolerated treatment options that do not interfere with the natural properties of hair and can effectively deliver therapeutic drug to the affected area including hair-bearing areas such as the scalp, or other areas of skin,” said Raj Chovatiya, MD, PhD, MSCI, associate professor at the Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research, and lead author of the publication. “These findings highlight that the ZORYVE foam formulation excludes harmful ingredients that are known to damage hair and includes a gentle emulsifier used for the first time in the pharmaceutical industry, which provides confidence in its use for patients without damaging the skin barrier or hair styles.”